002728 Teyi Pharmaceutical Group
- 9.38
- -0.17-1.78%
Teyi Pharmaceutical Group News
Special Pharmaceutical (002728.SZ): One of the Chinese herbal medicines used in cough medicine tablets is simply an extract extracted from poppy shell. Poppy shell is a nationally controlled medicinal herb, priced by the National Development and Reform Co
Gelonghui, April 24 | Teyi Pharmaceutical (002728.SZ) said on the investor interactive platform that one of the Chinese herbal medicines used in the company's cough medicine is simply an extract extracted from poppy shells. Poppy shell is a nationally controlled medicinal herb, and the price is set by the National Development and Reform Commission. In addition, the other raw materials needed for cough medicine tablets, such as aster, orange red, bellflower, citrus aurantium, and 100 parts, are all common Chinese herbal medicines on the market. The market supply is large, and there is no supply pressure. In addition, the company is equipped with a special warehouse for Chinese herbal medicines, so the company can make sufficient safe reserves according to subsequent market needs. Judging from the current level of consumption of Cough Remedies, Cough Remedies every day
Teyi Pharmaceutical (002728.SZ): The company holds approvals for drugs such as Qianbai rhinitis tablets, etc., and is currently not producing
On April 24, Gelonghui Pharmaceutical (002728.SZ) said on the investor interactive platform that the company holds pharmaceutical approvals for ketotifen fumarate tablets, chlorphenamine maleate tablets, nasal comfort tablets, and Qianbai rhinitis tablets, and are currently not producing them.
Teyi Pharmaceutical (002728.SZ): Net profit of 9.1546 million yuan in the first quarter decreased by 91.32% year on year
On April 19, Ge Longhui Pharmaceutical (002728.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 165 million yuan, down 45.88% year on year; net profit attributable to shareholders of listed companies was 9.1546 million yuan, down 91.32% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 8.924,600 yuan, down 91.51% year on year; basic earnings per share were 0.03 yuan.
Teyi Pharmaceutical (002728): Leading brands of traditional Chinese medicine are reviving under a two-pronged approach of channels and new products
Recommended logic: In the context of policies encouraging traditional Chinese medicine, the company focuses on specialty proprietary Chinese medicines and is expected to usher in a new stage of rapid development. 1) Cough Remedies are the company's core variety and have a century-old brand history. “Capacity expansion+channel transformation” is expected to drive this
Teyi Pharmaceutical (002728.SZ): The ban on 2014.65 million restricted shares will be lifted on April 11
Gelonghui, April 8, 丨 Teyi Pharmaceutical (002728.SZ) announced an indicative announcement on the issuance of restricted shares to specific targets in 2023. The number of restricted shares lifted this time is 201465.14 million shares, accounting for 5.5235% of the company's total share capital at present. The current limited-sale stock listing circulation date is April 11, 2024 (Thursday).
Medical beauty stocks fell collectively. Among them, Jiangsu Wuzhong fell to a standstill, Aimeike fell more than 9%, Jingfeng Pharmaceutical fell more than 5%, Huadong Pharmaceutical, Betaini, and Guanhao Biotech fell more than 4%, and Teyi Pharmaceutica
Medical beauty stocks fell collectively. Among them, Jiangsu Wuzhong fell to a standstill, Aimeike fell more than 9%, Jingfeng Pharmaceutical fell more than 5%, Huadong Pharmaceutical, Betaini, and Guanhao Biotech fell more than 4%, and Teyi Pharmaceutical, Shuyu Pingmin, Changshan Pharmaceutical, and Dian Diagnosis fell more than 3%.
Express News | Teyi Pharmaceutical: The company's drug passed the consistency evaluation for acetaminophen tablets
Teyi Pharmaceutical (002728.SZ): Currently there is no planting base for Chinese herbal medicines
Gelonghui, March 22丨Teyi Pharmaceutical (002728.SZ) said on the investor interactive platform that all Chinese herbal medicines required by the company to produce proprietary Chinese medicines are purchased from outside, and there is currently no Chinese herbal medicine cultivation base.
Teyi Pharmaceutical (002728.SZ): No research or plans on weight loss drugs
Gelonghui March 22丨Teyi Pharmaceutical (002728.SZ) said on the investor interactive platform that the company has no research or plans on diet pills yet.
Teyi Pharmaceutical (002728.SZ): Cardiovascular products mainly include blood clotong dispersible tablets, Yixinshu granules, ginkgo biloba dispersible tablets, captopril tablets, etc.
On March 11, Gelonghui Pharmaceutical (002728.SZ) said on the investor interactive platform that the company has a wide range of pharmaceuticals. The main cardiovascular products include blood clotting dispersible tablets, Yixinshu granules, ginkgo biloba dispersible tablets, and captopril tablets. The company has always attached importance to investment in R&D, and regards R&D as the driving force for enterprise development. In the later stages, it will continue to increase R&D and innovation efforts according to R&D and market demand. The company's R&D focus is mainly on proprietary Chinese medicines: first, continue to promote some innovative traditional Chinese medicine drugs and improved new drugs to achieve marketing and sales goals as soon as possible; second, through clinical research or real-world research, on characteristics
Teyi Pharmaceutical (002728): Strong growth in cough medicine, actively promoting changes in marketing organization
Incident: The company released its 2023 annual report and achieved operating income, net profit attributable to mother, and net profit excluding non-return to mother of RMB 10.67/2.53/249 million, respectively, +20.38%/42.07% /43.61 compared with the same period last year
Teyi Pharmaceutical (002728.SZ): Net profit increased by 42.07% to 253 million yuan in 2023, plans to convert 10 to 4 to 5 yuan
Gelonghui, March 7 | Teyi Pharmaceutical (002728.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,067 million yuan, an increase of 20.38%; achieved net profit attributable to shareholders of listed companies of 253 million yuan, an increase of 42.07% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 249 million yuan, an increase of 43.61% year on year; basic income per share is 0.77 yuan; it plans to distribute cash dividends of 5.00 yuan (tax included) to all shareholders for every 10 shares, using capital reserves to the whole Shareholders added 4 shares for every 10 shares.
Teyi Pharmaceutical (002728.SZ): The drug ibuprofen tablets passed the consistency evaluation
On February 19, Gelonghui Pharmaceutical (002728.SZ) announced that the company recently obtained the “Drug Supplement Application Approval Notice” for “ibuprofen tablets” approved and issued by the State Drug Administration. After review, the above drugs passed the consistent evaluation of the quality and efficacy of chemical generic drugs. The ibuprofen tablets that passed the one-time evaluation this time have a total of 2 specifications, 0.1 g and 0.2 g, respectively (of which 0.2 g is a new specification). Ibuprofen tablets are used to relieve mild to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, neuralgia, and dysmenorrhea. It is also used for fever caused by the common cold or influenza.
Special Pharmaceutical (002728.SZ): Drugs cover categories such as cough relief, antipyretic, antibiotics, antiviral drugs, digestive system, etc.
Gelonghui, Feb. 6 | Special Pharmaceutical (002728.SZ) said on the investor interactive platform that influenza patients mainly showed fever, often with respiratory symptoms such as cough, sore throat, nasal congestion, and runny nose. It was accompanied by general discomfort such as headache and muscle aches, and some experienced gastrointestinal discomfort. Looking at related symptoms, the company's drugs cover categories such as cough relief, fever relief, antibiotics, antiviral drugs, and digestive system. The company's core product, Cough Remedies, has a history of 100 years. It was famous in the late Qing Dynasty, and has the effect of “promoting lung expectoration, relieving cough and asthma”. In addition, the company's products are also small in terms of relieving cough and phlegm
Express News | Teyi Pharmaceutical: Currently, the production and sales of Cough Remedies are normal
Teyi Pharmaceutical (002728.SZ): The cost of cough medicine products has not increased much, and their gross sales margin has remained stable
Gelonghui January 19丨Teyi Pharmaceutical (002728.SZ) was surveyed by a specific target on January 18, 2024, on “Is the raw material price of Cough Remedies relatively stable?” The company replied that the main raw material for cough medicine tablets is an extract extracted from poppy shells. The poppy shells purchased by the company are purchased from the national agricultural reclamation in Gansu according to the purchase application approved by the State Drug Administration. The price is set by the National Development and Reform Commission, and the adjustment is small; overall, the procurement costs of other Chinese herbal medicines purchased by the company are on an upward trend, but the company generally formulates raw materials based on market demand and raw material supply and demand
Teyi Pharmaceutical (002728.SZ): Will pharmacies account for a certain period of later sales
Gelonghui, January 19丨Teyi Pharmaceutical (002728.SZ) was surveyed by a specific target on January 18, 2024, on “What is the proportion of the top 100 chains, ordinary chains, and late-stage third terminals?” The company replied that since the company's marketing team is currently still in the formation stage and needs to further accumulate sales experience, the company will further improve the marketing network construction, increase sales and business promotion efforts for the top 100 pharmacy chains in the country and key regional pharmacy chains, and increase the market coverage and growth of the company's cough medicine in pharmacy chains. At the same time, develop a third terminal and increase marketing channels. At some point in the later stages
Teyi Pharmaceutical (002728.SZ): It is expected to launch two to three kinds of proprietary Chinese medicines every year
Gelonghui, January 19丨Teyi Pharmaceutical (002728.SZ) was surveyed by specific subjects on January 18, 2024. “Did the new varieties launched by the company mainly come from the original drug approval?” The company replied that the company has sufficient reserves of drug approvals, and later mainly launched the company's original drug approvals. The company expects to launch two to three proprietary Chinese medicines every year, such as skin disease blood poison pills, sugar reduction pills, and Fengliao gastrointestinal health tablets introduced in recent years. At the same time, the company also continues to strengthen brand building, strives to build the “special” brand into a brand with significant market influence, and increase the company's market popularity and
Teyi Pharmaceutical (002728.SZ): There are many reserves of proprietary Chinese medicine products, and the market capacity of some proprietary Chinese medicine products is large
Gelonghui, January 19丨Teyi Pharmaceutical (002728.SZ) was surveyed by a specific target on January 18, 2024, on “Will the company focus on developing proprietary Chinese medicines in the future? Proprietary Chinese medicine's revenue share?” The company replied that the company has large reserves of proprietary Chinese medicine products and that some proprietary Chinese medicine products have a large market capacity. In the context of the national industrial policy strongly supporting the development of the traditional Chinese medicine industry, the company will keep up with the major trends of national reform and development and focus on developing proprietary Chinese medicine varieties. As of 2022, the company's proprietary Chinese medicines and chemical pharmaceutical products all accounted for about 45% of revenue, and chemical raw materials and chemical products accounted for about 45% of revenue
Teyi Pharmaceutical (002728.SZ): In recent years, in-hospital revenue has accounted for about 8%, accounting for a small proportion
Gelonghui January 19丨Teyi Pharmaceutical (002728.SZ) was surveyed by a specific target on January 18, 2024. “Is the company's main sales channel OTC? What is the percentage of the hospital?” The company replied that the company's products are mainly OTC products, which mainly enter pharmacies and clinics through dealers; they are varieties of national essential drugs and prescription drugs, which are distributed to hospitals, clinics, etc. through dealers. Basically, these products that enter hospitals or clinics are all low-cost pharmaceutical products. In recent years, in-hospital income has accounted for around 8%, which is a small proportion.
Analysis
Price Target
No Data
